Analyst Price Targets — BHC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 7, 2026 12:19 pm | Les Sulewski | Truist Financial | $8.00 | $7.63 | TheFly | Bausch Health price target raised to $8 from $7 at Truist |
| December 8, 2025 9:25 pm | Glen Santangelo | Barclays | $8.00 | $6.82 | TheFly | Bausch Health initiated with an Equal Weight at Barclays |
| October 23, 2024 11:34 am | Douglas Miehm | RBC Capital | $10.00 | $8.07 | TheFly | Bausch Health price target raised to $10 from $8.50 at RBC Capital |
| July 25, 2024 9:08 am | Les Sulewski | Truist Financial | $7.00 | $5.69 | TheFly | Bausch Health price target lowered to $7 from $8 at Truist |
| July 10, 2024 8:13 am | Michael Freeman | Raymond James | $8.00 | $7.19 | TheFly | Bausch initiated with Market Perform on Xifaxan risk at Raymond James |
| April 29, 2024 7:39 am | David Amsellem | Piper Sandler | $9.00 | $8.78 | StreetInsider | Bausch Health Companies (BHC) PT Raised to $9 at Piper Sandler |
| April 23, 2024 6:08 am | Doug Miehm | RBC Capital | $11.00 | $8.45 | StreetInsider | Bausch Health Companies (BHC) PT Lowered to $11 at RBC Capital |
| April 11, 2024 11:29 am | Glen Santangelo | Jefferies | $16.00 | $9.28 | StreetInsider | Jefferies on BHC (BHC): 'We see this as an extremely positive outcome for BHC and removes a key barrier to executing the spin' |
| April 5, 2024 6:16 am | Doug Miehm | RBC Capital | $12.00 | $10.05 | StreetInsider | Bausch Health Companies (BHC) PT Raised to $12 at RBC Capital |
| September 9, 2022 6:34 am | — | Piper Sandler | $6.00 | $6.70 | Benzinga | Piper Sandler Maintains Neutral on Bausch Health Companies, Lowers Price Target to $6 |
Latest News for BHC
Bausch + Lomb said on Thursday its glaucoma eye drop had missed the main goal in a mid-stage trial of replicating visual function improvements observed in a smaller study.
LAVAL, QC, July 7, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release second quarter 2026 financial results after market close on Wednesday, July 29, 2026. Bausch Health will host a live conference call and webcast at 5:00 p.m.
LAVAL, QC, July 1, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced that Michael Goettler has resigned from its Board of Directors, effective June 30, 2026, in connection with his appointment as President and Chief Executive Officer of Knoa Pharma LLC. "We thank Michael for his valued service and wish him the best in his new role," said John A.
Bausch (BHC) reported earnings 30 days ago. What's next for the stock?
Thermage ® , a pioneer in non-invasive skin tightening, was awarded the AAA Well-Known Trademark Certification, the highest recognition in China's domestic trademark evaluation system. LAVAL, QC, May 28, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in the medical aesthetics market, are proud to announce that…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BHC.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.